HER2-targeted therapies for patients with HER2+ breast cancer are rapidly evolving,
offering a range of more complex and personalized treatment options. Currently, an array of …

HER2-positive breast cancer is highly aggressive, with a significant risk of recurrence and
metastasis, leading to a poor prognosis. While most early-stage HER2-positive breast …

Purpose: The purpose of this study was to assess the predictive capability of HER2DX assay
following (neo) adjuvant trastuzumab–pertuzumab (HP)–based therapy in HER2-positive …

Background Persistent debates exist regarding the superiority of neoadjuvant therapy (NAT)
over adjuvant therapy (AT) for patients with T1c, node‐negative, human epidermal growth …

Background Early-stage triple-negative breast cancer (TNBC) displays clinical and
biological diversity. From a biological standpoint, immune infiltration plays a crucial role in …

Background For patients with breast cancer undergoing neoadjuvant chemotherapy (NACT),
most of the existing prediction models of pathologic complete response (pCR) using …

HER2-positive breast cancer is an aggressive subtype that accounts for 15% to 20% of all
breast cancers. Recent studies have suggested that HER2-positive breast cancer is a group …

Opinion Statement This perspective underscores the evolution and significance of
neoadjuvant therapy in breast cancer, tracing its history and efficacy in improving outcomes …

Simple Summary Almost one in five patients with breast cancer have an aggressive subtype
that expresses Human Epidermal Growth Factor-2 (HER2) receptor. The introduction of anti …

Introduction Breast cancer is one of the most prevalent malignant tumors globally, posing a
severe threat to human life and health. Chemotherapy, a cornerstone in the treatment of …